NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)

The National Institutes of Health, within the U.S. Department of Health and Human Services, administers the Small Business Innovation Research program to stimulate technological innovation and foster commercialization of federally funded research. This funding opportunity, identified as the Parent SBIR Clinical Trial Optional mechanism, supports United States small business concerns in developing scientific innovations that have the potential to be translated into marketable products or services. The program aligns with federal priorities to strengthen domestic research capacity, improve public health outcomes, and accelerate the transition of early-stage discoveries into practical applications. The primary purpose of this opportunity is to provide phased support for research and development activities conducted by small businesses. The funding is structured to enable feasibility studies and subsequent development work, allowing applicants to validate concepts and progress toward commercialization. While specific funding amounts are not provided in the synopsis, the program traditionally supports both early-stage exploratory work and more advanced development through phased awards, enabling companies to advance technologies across the innovation pipeline. Eligible applicants are limited to United States-based small business concerns as defined by the Small Business Administration. Foreign organizations and non-domestic components of U.S. organizations are not eligible to apply, although limited unfunded international collaborations may be permitted. The program is nationwide in scope, allowing participation from qualifying entities across all U.S. states and territories without geographic restriction. This inclusivity reflects the federal objective of promoting innovation across diverse regions and industries. Applications must be submitted through standard federal grant submission systems, typically involving registration with Grants.gov and compliance with NIH submission requirements. While the synopsis does not detail specific application components, SBIR applications generally require a research plan, commercialization strategy, budget justification, and supporting documentation demonstrating technical feasibility and business viability. Evaluation criteria typically include scientific merit, innovation, investigator qualifications, and commercial potential. The application timeline indicates that the opportunity is currently open and accepting submissions, with a stated closing date of April 5, 2027. No pre-application requirements such as letters of intent are specified in the available materials. The absence of explicit rolling language suggests a fixed deadline structure, though the SBIR parent announcement is commonly reissued, indicating a recurring funding opportunity. Applicants are encouraged to plan submissions in advance of the closing date to ensure compliance with all federal requirements. Contact for the program is provided through the NIH SEED office, which supports small business applicants with guidance and technical assistance. Communication is facilitated via a centralized email inbox, ensuring accessibility for prospective applicants seeking clarification. While award notification timelines and performance periods are not specified in the synopsis, NIH SBIR awards typically follow a structured review and funding cycle, with project periods varying depending on the phase of the award.